Abstract | BACKGROUND: METHODS: RESULTS: Among the 10 patients, 9 were available for the efficacy evaluation. There were 5 with partial response, 2 with stable disease and 2 with progressive disease. The objective response rate and the disease control rate (DCR) were 55% (5/9) and 78% (7/9), respectively. The median progress free survival time was 8.3 months. As for safety analysis, the most 3 common adverse events were gastrointestinal reaction (31.8%), hypertension (22.7%), and myelosuppression (18.0%). CONCLUSION:
Apatinib combined with irinotecan seems to be a promising therapeutic option for recurrent malignant glioma patients. Perspective clinical studies with adequate sample size are required to validate our results. TRIAL REGISTRATION: NCT02848794 /Ahead-BG306.
|
Authors | Lei Wang, Lijun Liang, Tao Yang, Yun Qiao, Youyou Xia, Liang Liu, Chao Li, Peizhi Lu, Xiaodong Jiang |
Journal | Medicine
(Medicine (Baltimore))
Vol. 96
Issue 49
Pg. e9053
(Dec 2017)
ISSN: 1536-5964 [Electronic] United States |
PMID | 29245310
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Pyridines
- apatinib
- Irinotecan
- Camptothecin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Female
- Glioma
(drug therapy, pathology)
- Humans
- Irinotecan
- Male
- Middle Aged
- Neoplasm Grading
- Neoplasm Recurrence, Local
(drug therapy, pathology)
- Pilot Projects
- Pyridines
(administration & dosage)
- Treatment Outcome
|